50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
What’s the Obsession Over Inflation? (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What’s the Obsession Over Inflation? (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
What’s the Obsession Over Inflation? (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What’s the Obsession Over Inflation? (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
What’s the Obsession Over Inflation? (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What’s the Obsession Over Inflation? (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
What’s the Obsession Over Inflation? (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
What’s the Obsession Over Inflation? (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
OTCMKTS:NWBO

Northwest Biotherapeutics - NWBO Stock Forecast, Price & News

$0.71
0.00 (0.00%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.68
$0.72
50-Day Range
$0.62
$0.78
52-Week Range
$0.39
$2.05
Volume
1.50 million shs
Average Volume
2.51 million shs
Market Capitalization
$739.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NWBO stock logo

About Northwest Biotherapeutics (OTCMKTS:NWBO) Stock

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Receive NWBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

NWBO Stock News Headlines

NWBO Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics Announces $15 Million Financing
Northwest Biotherapeutics Inc (NWBO)
Is Arko Corp. (ARKO) A Good Stock To Buy?
Northwest Bio: The Endgame Is Approaching
3 Penny Stocks To Buy On Robinhood Under $3 Right Now
See More Headlines
Receive NWBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

NWBO Company Calendar

Last Earnings
8/09/2022
Today
9/28/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:NWBO
Previous Symbol
NASDAQ:NWBO
Employees
19
Year Founded
N/A

Profitability

Net Income
$179.13 million
Pretax Margin
10,972.12%

Debt

Sales & Book Value

Annual Sales
$1 million
Cash Flow
$0.19 per share
Book Value
($0.13) per share

Miscellaneous

Outstanding Shares
1,045,811,000
Free Float
900,443,000
Market Cap
$739.39 million
Optionable
Not Optionable
Beta
0.18

Key Executives

  • Ms. Linda F. Powers J.D. (Age 66)
    Chairperson, CEO, Pres, CFO & Chief Accounting Officer
    Comp: $1M
  • Dr. Alton L. Boynton (Age 77)
    Founder, Chief Scientific Officer, Sec. & Director
  • Dr. Marnix L. Bosch M.B.A. (Age 63)
    Ph.D., MBA, Chief Technical Officer
    Comp: $605k
  • Mr. Leslie J. Goldman (Age 77)
    Sr. VP & Gen. Counsel
    Comp: $725k
  • Ms. Jean M. Davis (Age 50)
    Chief Information Officer
  • Mr. David Innes
    VP of Investor Relations
  • Mr. Pankaj R. Shah C.A.
    CPA, Financial Controller













NWBO Stock - Frequently Asked Questions

How have NWBO shares performed in 2022?

Northwest Biotherapeutics' stock was trading at $0.70 at the start of the year. Since then, NWBO stock has increased by 1.0% and is now trading at $0.7070.
View the best growth stocks for 2022 here
.

When is Northwest Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NWBO earnings forecast
.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) issued its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.03) EPS for the quarter. The biotechnology company had revenue of $0.48 million for the quarter.

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA), TransEnterix (TRXC), Amarin (AMRN), Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP).

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $0.71.

How much money does Northwest Biotherapeutics make?

Northwest Biotherapeutics (OTCMKTS:NWBO) has a market capitalization of $739.39 million and generates $1 million in revenue each year.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The official website for the company is www.nwbio.com. The biotechnology company can be reached via phone at (240) 497-9024, via email at lgoldman@nwbio.com, or via fax at 240-627-4121.

This page (OTCMKTS:NWBO) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.